Rigel Pharmaceuticals price target raised to $8 at Piper Jaffray. Piper Jaffray analyst Christopher Raymond raised his price target on Rigel Pharmaceuticals to $8 from $7 following the company’s Q1 update and its discussions around the launch plans for Tavalisse. The analyst says the update was necessary to demonstrate the company’s ability to execute commercially. Raymond keeps his Overweight rating on Rigel Pharmaceuticals.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.